BioSpace News Archive

OliX has been developing novel delivery approaches for siRNAs to the lung tissue OliX’s local pulmonary administration of siRNA drugs through nebulization may contribute to improved treatment efficacy OliX’s previous research on idiopathic pulmonary fibrosis shows that inhaled siRNA formulation allows effective knockdown of target genes expressed in the lung tissue in animal models OliX plans to secure cp-asiRNA lead compounds ready for animal model testing in approximately 3 months SUWON,

CABENUVA™ offers adults living with HIV a new once-monthly injectable option for maintaining viral suppression

AIkido Pharma Incorporated (Nasdaq: AIKI) today announced the addition of Andreas Typaldos to the Company’s Advisory Board.

launch of the NYC COVID-19 Response & Impact Fund to support New York City-based social services and arts and cultural organizations that have been affected by the current coronavirus public health crisis.

Vuzix® Corporation (NASDAQ: VUZI), (“Vuzix” or, the “Company”), a leading supplier of Smart Glasses and Augmented Reality (AR) technology and products, today announced that the Vuzix Blade ® Smart Glasses have been selected by X.Labs, developer of SWORD weapon detection system, as the optional smart glasses companion for Feevr.

As part of the U.S. Food and Drug Administration’s ongoing commitment to address the coronavirus (COVID-19) pandemic, the agency has issued two guidance documents to communicate its policy for the temporary manufacture of certain alcohol-based hand sanitizer products.

Within the last week, many Americans who are afflicted with chronic back pain have been informed their back surgery has been canceled due to COVID-19.

The COVID-19 outbreak continues to evolve rapidly, and the government is mobilizing Canadian businesses and manufacturers to help fight the spread of the virus and protect the health and safety of all Canadians.

Itamar Medical Ltd. (Nasdaq: ITMR) (TASE: ITMR), a medical technology company focused on the development and commercialization of non-invasive medical devices to aid in the diagnosis of respiratory sleep disorders, today released the following letter from its President and CEO, Gilad Glick.

Adaptive Biotechnologies Corp. (Nasdaq: ADPT) and Microsoft Corp. (Nasdaq: MSFT) on Friday announced they will leverage their existing partnership mapping population-wide adaptive immune responses to diseases at scale to study COVID-19.